Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder

Basit Öğe Kaydı
dc.authorid0000-0003-0128-6947
dc.authorid0000-0001-9636-4113
dc.contributor.authorYiğit Kaya, Süreyya
dc.contributor.authorAşkın, Abdullah Emre
dc.contributor.authorBektaş, Şebnem
dc.contributor.authorÇakır, Aslı
dc.contributor.authorGökmen Sevindik, Ömür
dc.date.accessioned2023-05-24T07:42:19Z
dc.date.available2023-05-24T07:42:19Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractAllogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an effective option for the treatment of intermediate and high-risk Acute myeloid leukemia (AML). Post-transplant lymphoproliferative disorder (PTLD) is related to the intensity of post-transplant immunosuppression. Although Epstein-Barr virus (EBV) seropositivity and reactivation can be a major risk factor for PTLD. A few PTLDs could be EBV negative. There are a very limited number of PTLD cases following HSCT in patients with AML. We present a differential diagnosis of cytopenias after allo-HSCT. This is the first report of an AML patient developing bone marrow EBV-negative PTLD relatively late in their post-transplant course.
dc.identifier.citationYiğit Kaya, S., Aşkın, A. E., Bektaş, Ş., Çakır, A. ve Gökmen Sevindik, Ö. (2023). Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder. Leukemia Research Reports, 19. https://doi.org/10.1016/j.lrr.2023.100369
dc.identifier.doi10.1016/j.lrr.2023.100369
dc.identifier.issn2213-0489
dc.identifier.pmid37213444
dc.identifier.scopus2-s2.0-85156144672
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1016/j.lrr.2023.100369
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10965
dc.identifier.volume19
dc.identifier.wos001051640000001en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorYiğit Kaya, Süreyya
dc.institutionauthorAşkın, Abdullah Emre
dc.institutionauthorBektaş, Şebnem
dc.institutionauthorÇakır, Aslı
dc.institutionauthorGökmen Sevindik, Ömür
dc.language.isoen
dc.publisherElsevier Ltd
dc.relation.ispartofLeukemia Research Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAcute Myeloid Leukemia (AML)
dc.subjectEpstein-Barr Virus
dc.subjectPost Transplant Lymphoproliferative Disorder
dc.subjectRituximab
dc.titleNewly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Yiğit Kaya-Süreyya-2023.pdf
Boyut:
277.55 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu